Skip to content

Climb Bio, Inc. CLYM Net Change in Cash

Net Change in Cash at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
-$635M-220%
Amgen logo
AmgenAMGN
$2.91B+192%
Vera Therapeutics logo
Vera TherapeuticsVERA
-$240.37M-540%
Kyverna Therapeutics, Inc. logo
Kyverna Therapeutics, Inc.KYTX
-$91.9M-131%
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
-$13.25M-109%
Jade Biosciences, Inc. Common Stock logo
Jade Biosciences, Inc. Common StockJBIO
-$33.35M-71.4%

Other financials

Income statement

See full
Operating income-$15.2M+33.9%
Net income-$13.7M+34.0%
EPS (diluted)-$0.20+35.5%

Balance sheet

See full
Cash & equivalents$8.4M-71.2%
Total debt$479.0K+1.1%
Total equity$148.1M-23.4%
Total assets$152.4M-24.1%

Cash flow

See full
Operating cash flow-$14.4M+6.8%
CapEx$109.0K
Free cash flow-$15.6M-183%

Valuation

See full
Market cap$724.95M+787%
Enterprise value$717.07M+1,247%

Returns & leverage

See full
Return on equity-30.9%-10.3pp
Debt / equity0.0×
Current ratio27.9×+13.6×

Where this comes from

Reported directly by Climb Bio, Inc. in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect.

The official record: Climb Bio, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Climb Bio, Inc.'s net change in cash.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Climb Bio, Inc.'s net change in cash?
Climb Bio, Inc. (CLYM) reported net change in cash of -$27.33M in Q1 2026.
How has Climb Bio, Inc.'s net change in cash changed year-over-year?
Climb Bio, Inc.'s net change in cash increased by 53.1% year-over-year, from -$58.21M to -$27.33M.
What does net change in cash mean?
Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.